Revaprazan

Revaprazan (trade name Revanex) is a drug that reduces gastric acid secretion which is used for the treatment of gastritis.[2] It acts as an acid pump antagonist[3] (potassium-competitive acid blocker). Revaprazan is approved for use in South Korea,[4] but is not approved in Europe or the United States.

Revaprazan

Clinical data
Trade names	Revanex[1]
Other names	YH1885
ATC code	None
Identifiers
IUPAC name N-(4-Fluorophenyl)-4,5-dimethyl-6-(1-methyl-3,4-dihydro-2(1H)-isoquinolinyl)-2-pyrimidinamine
CAS Number	199463-33-7
PubChem CID	204104
ChemSpider	176801
UNII	5P184180P5
Chemical and physical data
Formula	C22H23FN4
Molar mass	362.452 g·mol^−1
3D model (JSmol)	Interactive image
SMILES c1cc(F)ccc1Nc2nc(C)c(C)c(n2)N3CCc4ccccc4C3C
InChI InChI=1S/C22H23FN4/c1-14-15(2)24-22(25-19-10-8-18(23)9-11-19)26-21(14)27-13-12-17-6-4-5-7-20(17)16(27)3/h4-11,16H,12-13H2,1-3H3,(H,24,25,26) Key:LECZXZOBEZITCL-UHFFFAOYSA-N

References

1. "Revaprazan". drugs.com.
2. Kim HK, Park SH, Cheung DY, Cho YS, Kim JI, Kim SS, Chae HS, Kim JK, Chung IS (Oct 2010). "Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects". J Gastroenterol Hepatol. 25 (10): 1618–1625. doi:10.1111/j.1440-1746.2010.06408.x. PMID 20880169.
3. Yu KS, Bae KS, Shon JH, Cho JY, Yi SY, Chung JY, Lim HS, Jang IJ, Shin SG, Song KS, Moon BS (Jan 2004). "Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers". J Clin Pharmacol. 44 (1): 73–82. doi:10.1177/0091270003261321. PMID 14681344.
4. "Revaprazan Yuhan registered, South Korea (gastritis)". R & D Focus Drug News. September 25, 2006. Archived from the original on April 29, 2014.